ArticleZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences2026
[Quercetin, a key bioactive component of Zuogui Pill, protects against Alzheimer
Article in Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the protective mechanism of quercetin, a key bioactive component of Chinese medicine Zuogui Pill, against Alzheimer's disease (AD) via the PI3K/Akt signaling pathway.
methodsThe TCMSP, PubChem, SwissTargetPrediction, and BATMAN-TCM databases were used to retrieve the active components of Zuogui Pill and predict their potential targets. Target information was standardized using the UniProt database. AD-related target genes were obtained from DrugBank, GeneCards, and OMIM, and the intersection was taken to identify the potential targets of Zuogui Pill for AD treatment. Based on these targets, a protein-protein interaction network was constructed using Cytoscape 3.10.1 and the STRING database. The key active components and core targets of Zuogui Pill for AD treatment were identified through computational analysis. Gene Ontology functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis were performed on the potential targets to explore the biological processes and signaling pathways involved. Subsequently, molecular docking and binding affinity prediction between the key active component quercetin and the core target Akt1 were performed using the online tool CB-Dock2. An AD cell model was established by treating mouse hippocampal neuron cells (HT22) with amyloid β-protein
resultsNetwork pharmacology demonstrated that quercetin targets core proteins such as Akt1 in a network manner and is predominantly enriched in the PI3K/Akt signaling pathway. Molecular docking showed favorable binding affinity between quercetin and Akt1 (binding energy: －6.6 kcal/mol). In the Aβ
conclusionsQuercetin, a key bioactive component of Chinese medicine Zuogui Pill, inhibits neuronal apoptosis by regulating the PI3K/Akt signaling pathway, thereby exerting a protective effect against AD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.